Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

NCT01516515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2018-12-05

No results posted yet for this study

Summary

This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).

Conditions

  • Actinic Keratosis

Interventions

DRUG

Vehicle gel

placebo

DRUG

SR-T100 with 2.3% of SM

2.3% of SM in Solanum undatum plant extract

Sponsors & Collaborators

  • G&E Herbal Biotechnology Co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2017-12-31
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516515 on ClinicalTrials.gov